|Publication Type||Journal Article|
|Year of Publication||2010|
|Authors||Sboner, A, Demichelis, F, Calza, S, Pawitan, Y, Setlur, SR, Hoshida, Y, Perner, S, Adami, HO, Fall, K, Mucci, LA, Kantoff, PW, Stampfer, M, Andersson, SO, Varenhorst, E, Johansson, JE, Gerstein, MB, Golub, TR, Rubin, MA, Andrén, O|
|Journal||BMC medical genomics|
Current prostate cancer prognostic models are based on pre-treatment prostate specific antigen (PSA) levels, biopsy Gleason score, and clinical staging but in practice are inadequate to accurately predict disease progression. Hence, we sought to develop a molecular panel for prostate cancer progression by reasoning that molecular profiles might further improve current clinical models.